Effect of nitroglycerin ointment on bone density and strength in postmenopausal women a randomized trial

JAMA

Volumn 305, Issue 8, 2011, Pages 800-807

  Jamal, Sophie A ^a   Hamilton, Celeste J ^b   Eastell, Richard ^c   Cummings, Steven R ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CALCIUM; GLYCERYL TRINITRATE; NITRATE; PLACEBO; VITAMIN D;

ADULT; ARTICLE; BEDTIME DOSAGE; BONE; BONE DENSITOMETRY; BONE DENSITY; BONE STRENGTH; BONE TURNOVER; CANADA; CORTICAL BONE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FEMUR NECK FRACTURE; FRACTURE; FRAGILITY FRACTURE; HIP; HIP FRACTURE; HUMAN; LUMBAR SPINE; LUMBAR SPINE FRACTURE; MAJOR CLINICAL STUDY; NAUSEA; OINTMENT; OSTEOLYSIS; OUTCOME ASSESSMENT; PERIOSTEUM; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PRURITUS; RADIUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPINE FRACTURE; STROKE; TIBIA; TREATMENT DURATION; TREATMENT OUTCOME; URINE; VITAMIN SUPPLEMENTATION;

EID: 79951991649     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.176     Document Type: Article

References (44)

1. Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178-208. (Pubitemid 15236006)
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733. (Pubitemid 44607392)
3. Ralston SH. The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas! Br J Rheumatol. 1997;36(8):831-838.
4. Brandi ML, Hukkanen M, Umeda T, et al. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci U S A. 1995;92(7):2954-2958.
5. Collin-Osdoby P, Nickols GA, Osdoby P. Bone cell function, regulation, and communication: a role for nitric oxide. J Cell Biochem. 1995;57(3):399-408.
6. Löwik CW, Nibbering PH, van de Ruit M, Papapoulos SE. Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. J Clin Invest. 1994;93(4):1465-1472. (Pubitemid 24116382)
7. MacIntyre I, Zaidi M, Alam AS, et al. Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc Natl Acad Sci U S A. 1991;88(7):2936-2940. (Pubitemid 21916535)
8. Kasten TP, Collin-Osdoby P, Patel N, et al. Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc Natl Acad Sci U S A. 1994;91(9):3569-3573. (Pubitemid 24139471)
9. Wimalawansa SJ, Chapa MT, Yallampalli C, Zhang R, Simmons DJ. Prevention of corticosteroid-induced bone loss with nitric oxide donor nitroglycerin in male rats. Bone. 1997;21(3):275-280. (Pubitemid 27404085)
10. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone. 1996;18(4):301-304. (Pubitemid 26149339)
11. Wimalawansa S, Chapa T, Fang L, Yallampalli C, Simmons D, Wimalawansa S. Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. J Bone Miner Res. 2000;15(6):1119-1125. (Pubitemid 30350074)
12. Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res. 1998;13(11):1755-1759. (Pubitemid 28492006)
13. Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res. 2006;21(11):1811-1817. (Pubitemid 46141238)
14. Jamal SA, Cummings SR, Hawker GA. Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial. J Bone Miner Res. 2004;19(9):1512-1517. (Pubitemid 41094353)
15. Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab. 2009;94(9):3356-3364.
16. Block G, Hartman AM, Naughton D. A reduced dietary questionnaire: development and validation. Epidemiology. 1990;1(1):58-64. (Pubitemid 20255624)
17. Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10)(Suppl):S1-S34.
18. Osteomark NTx Urine Product Description. Princeton, New Jersey: Iverness Medical Innovations; 2011.
19. Metra BAP. EIA kit. San Diego, California: Quidel Corporation; 2002:8012.
20. Wallin J, Sjövall J. Detection of adverse drug reactions in a clinical trial using two types of questioning. Clin Ther. 1981;3(6):450-452. (Pubitemid 11092515)
21. Abshagen U, Spörl-Radun S. First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol. 1981;19(6):423-429. (Pubitemid 11067790)
22. Cummings SR, Palermo L, Browner W, et al; Fracture Intervention Trial Research Group. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JAMA. 2000;283(10):1318-1321. (Pubitemid 30129799)
23. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288(15):1889-1897. (Pubitemid 35168145)
24. Cummings SR, Black D. Bone mass measurements and risk of fracture in Caucasian women: a review of findings from prospective studies. Am J Med. 1995;98(2A):24S-28S.
25. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077-2082. (Pubitemid 29014065)
26. Black DM, Greenspan SL, Ensrud KE, et al; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-1215. (Pubitemid 37152030)
27. Black DM, Cummings SR, Karpf DB, et al; Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541. (Pubitemid 26411651)
28. Harris ST, Watts NB, Genant HK, et al; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344-1352. (Pubitemid 29483192)
29. Black DM, Delmas PD, Eastell R, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. (Pubitemid 46698462)
30. Cummings SR, San Martin J, McClung MR, et al; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
31. Ettinger B, Black DM, Mitlak BH, et al; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal womenwith osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637-645. (Pubitemid 29384151)
32. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441. (Pubitemid 32402100)
33. Chow JW, Fox SW, Lean JM, Chambers TJ. Role of nitric oxide and prostaglandins in mechanically induced bone formation. J Bone Miner Res. 1998;13(6):1039-1044. (Pubitemid 28265283)
34. van't Hof RJ, Ralston SH. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res. 1997;12(11):1797-1804.
35. Ake Y, Saegusa Y, Matsubara T, Mizuno K. Cultured osteoblast synthesize nitric oxide in response to cytokines and lipopolysaccharide. Kobe J Med Sci. 1994;40(3-4):125-137.
36. Sornay-Rendu E, Boutroy S, Munoz F, Delmas PD. Alterations of cortical and trabecular architecture are associated with fractures in postmenopausal women, partially independent of decreased BMD measured by DXA: the OFELY study. J Bone Miner Res. 2007;22(3):425-433. (Pubitemid 46797126)
37. Vico L, Zouch M, Amirouche A, et al. High-resolution pQCT analysis at the distal radius and tibia discriminates patients with recent wrist and femoral neck fractures. J Bone Miner Res. 2008;23(11):1741-1750.
38. Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90(12):6508-6515. (Pubitemid 41759306)
39. Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal womenwith osteoporosis. Osteoporos Int. 2011;22(1):357-362.
40. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886-1894.
41. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010;25(12):2282-2295.
42. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med. 2003;349(4):327-334. (Pubitemid 36886238)
43. Black DM, Bouxsein ML, Marshall LM, et al; Osteoporotic Fractures in Men (MrOS) Research Group. Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT. J Bone Miner Res. 2008;23(8):1326-1333. (Pubitemid 352040188)
44. Cummings SR Sr. A 55-year-old woman with osteopenia. JAMA. 2006;296(21):2601-2610.